Skip to content
Ancell Corporation
Search
  • Shopping Cart
  • Contact Us / US Orders
  • International Orders
  • Terms
Ancell Corporation
Search
  • Home
  • Shopping Cart
  • Contact Us /US Orders
  • International Orders
  • Terms
  • Procedures
  • Material Safety Data Sheet (MSDS)
  • Hot Topics
  • Home
  • Products
    • New Products
    • Anti-Human Antibodies
    • Anti-Mouse Antibody
    • Cytokine related
    • Immune Checkpoint
    • Isotype Controls
    • Progenitor/Stem Cell
    • Recombinant Proteins
    • Second-Step Reagents
    • TNF Superfamily
  • Information
    • Hot Topics
    • US Orders / Price lists
    • International Orders
    • Procedures
    • MSDS

Ancell anti-CTLA-4 mAb used to evaluate autoimmune ACS model

By Paul Everson / October 31, 2023

Acute Coronary Syndrome(ACS) was simulated by provoking healthy PBMC with autoimmune self antigen pepetide LL-37. Effect of blockade on HLA Class I, Class II, PD-1 and CTLA-4 on T cell expression of Activation Induced Molecules (AIM) was then examined.

“Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome” Chernomordik F, PC Dermayuga, et al. Front. Immunol., 27 March 2023 Volume 14 –https://doi.org/10.3389/fimmu.2023.1113904. PMID: 37051254

Relevant Ancell Research products

anti-human CD4 mAb

anti-human CD8 mAb

anti-human CD25 mAb

anti-human CD69 mAb

anti-human CD134(OX40) mAb

anti-human CD137 (4-1BB) mAb

anti-human CD152(CTLA-4) mAb

anti-human CD279(PD-1) mAb

anti-human HLA Class I mAb

anti-human HLA Class II mAb

← Previous Post
Next Post →

All prices are in U.S. dollars. International prices may vary.

Copyright © 2025 Ancell Corporation. All rights reserved.